---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-045657"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:23:24.889033+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)

## Summary
- Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)
- FY2024 guidance raised: revenue >$415M (from >$400M), GAAP net income >$120M (from >$105M), Adj. EBITDA >$160M (from >$150M)
- FY2025 guidance raised: revenue >$465M, net income >$165M, Adj. EBITDA >$215M
- Appointed KPMG as new independent registered public accounting firm, replacing CohnReznick after 17 years
- ASCENIV now >50% of revenue; sBLA filing planned for label expansion; pediatric study database lock in Q4 2024

## SEC filing metadata
- accession: 0001140361-24-045657
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124045657/0001140361-24-045657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124045657/ef20038149_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-045657
- JSON: https://secwatch.observer/filing/0001140361-24-045657.json
- Plain text: https://secwatch.observer/filing/0001140361-24-045657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.